{"title":"Insilico Medicine Nominates ISM5059, the Peripheral-restricted NLRP3 Inhibitor as Preclinical Candidate, for the Treatment of Multiple Inflammatory and Metabolism Indications","path":"/2026/02/05/insilico-medicine-nominates-ism5059-the-peripheral-restricted-nlrp3-inhibitor-as-preclinical-candidate-for-the-treatment-of-multiple-inflammatory-and-metabolism-indications/","site":"https://laotiantimes.com","atUri":"at://did:plc:svcthvzunxmjidtlw23zva6n/site.standard.document/3me4pervqzhp2","publishedAt":"2026-02-05T13:00:00Z","tags":"Cision PR Newswire"}